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Several studies have demonstrated the prognostic value of neutrophil‐lymphocyte ratio (NLR) in
patients with solid tumors and non–Hodgkin lymphoma. In contrast, there is only sparse data on
its prognostic role in patients with classical Hodgkin lymphoma (cHL). The aim of our study was
to establish whether NLR could serve as an independent prognostic factor in a cohort of 990
patients with nodular sclerosis (NS)‐cHL. After analysis of the log hazard ratio (HR) as a function
of NLR, we chose the value 6 as cutoff. Patients with NLR >6 had a worse progression‐free
survival and overall survival compared to those with NLR ≤6; 84% vs 75% and 92% vs 88%, at
5 years, with an HR of 1.65 and 1.82, respectively. Multivariate analysis showed that the risk
remained high with HR 1.44 and HR 1.54 in progression‐free survival and overall survival,
respectively. In summary, our study shows that NLR is a robust and independent prognostic
parameter in NS‐cHL, both in early and advanced disease. It is inexpensive and simple to apply.
Thus, we conclude that NLR, possibly in combination with the international prognostic score and
absolute monocyte count, is a useful guide for physicians treating NS‐cHL patients.
KEYWORDS
Hodgkin lymphoma, lymphocyte, neutrophil, neutrophil‐lymphocyte ratio, prognosis1 | INTRODUCTION
There is an increasing amount of published data showing that tumor
microenvironment, host immunity, and inflammatory responses all play
an important role in determining the clinical course and outcome of
patients with malignant lymphoma. Several investigators havethe Creative Commons Attribution
d, the use is non‐commercial and
lished by John Wiley & Sons Ltd.
wilconsidered the absolute lymphocyte count (ALC)1 as an important
biomarker of tumor infiltrating lymphocytes, reflecting host immunity
status, while absolute monocyte count (AMC)2 serves as a surrogate
biomarker of tumor‐associated macrophages within the tumor micro-
environment, and the absolute neutrophil count (ANC)3 as a measure
of the systemic inflammatory response to malignancy. Inflammation
is regarded as a critical component of tumor progression, and it is‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
eyonlinelibrary.com/journal/hon 561
562 MARCHESELLI ET AL.evident that the tumor microenvironment, is largely coordinated by
inflammatory cells, which play a central role in the neoplastic process,
promoting, proliferation, survival, and migration of tumor cell via
activation of signaling pathways.4–6 Both AMC and ALC have been
suggested as significant prognostic factors in Hodgkin lymphoma
(HL),1,7 while the ANC and the neutrophil lymphocyte ratio (NLR) at
diagnosis are both prognostic factors for survival in solid tumors8 and
recently have also been shown to have prognostic impact diffuse large
B‐cell lymphoma (DLBCL).3,9 In contrast, there is only sparse data on
their role as prognostic factors in patients with HL.10 In this regard
different cutoff values have been established for NLR in DLBCL
(3.5 or 4.0)3,9 and in HL (4.3).10 In the present retrospective study the
aim was to establish whether NLR could serve as a significant and
independent prognostic factor, utilizing a large cohort of patients with
nodular sclerosis (NS)‐HL.2 | PATIENTS AND METHODS
2.1 | Inclusion criteria
This is a retrospective study of previously untreated patientswithNS‐HL
diagnosed according to the World Health Organization criteria. We
reviewed the clinical and laboratory data of consecutive “therapy‐naive”
patients, treated in different centers in Italy and Israel from January 1988
to the end of December 2007, after approval by local institutional review
boards. Italian cases were collected from 38 centers belonging to the
Gruppo Italiano Studio Linfomi archive, while data from Israeli patients
were obtained from 2 medical centers. All studies were performed in
accordance with the Declaration of Helsinki. The inclusion criteria were
histopathological diagnosis of NS‐HL, no previous therapy, age
≥18 years, HIV negativity, availability of data on all clinical and laboratory
features and treatment given, data from long‐term follow‐up and out-
come. The database contained a total of 1855 patients who had received
combination chemotherapy with or without radiotherapy. Analysis was
performed on a final cohort of 990 patients, after the exclusion of those
with missing data relating to International Prognostic Score (IPS)
(n = 173), hematological and biochemical parameters (n = 193), missing
pathology report (n = 95), or other histologies (n = 404). Definition of
response was based on guidelines reported by Lister et al in 1989.112.2 | Outcomes
The primary end point of the study was to assess the impact of NLR on
progression‐free survival (PFS) and overall survival (OS).2.3 | Statistical analysis
Progression‐free survival was defined as the time from study entry to
the time of any documented clinical progression, relapse, or death from
any cause. Overall survival was defined as the time from study entry to
the last observation or death from any cause.
Patient baseline characteristics are expressed as absolute frequen-
cies and percentages for categorical variables and they are compared
with the χ2 test or exact Fisher test. Continuous variables were
reported as the median and 2.5‐97.5 percentile. Formal comparisonswere performed with Mann‐Whitney or Kruskal‐Wallis test. Survival
functions were evaluated with the Kaplan‐Meier method.12 Statistical
comparisons by groups of risk were performed with the log‐rank test
and the Cox proportional hazard (PH) regression analysis,13 with a
confidence interval at 95% (95% CI). The PH assumption was verified
graphically by means of scaled Schoenfeld residuals.14 The effect size
was reported as hazard ratio (HR) with the associated 95% CI.
2.3.1 | Analysis of the cutoff
We have assessed the NLR by modeling it as continuous covariate in
an explorative Cox PH restricted cubic spline regression.15 The
degrees of freedom for NLR were selected on the basis of the
minimum Akaike information criterion. The cutoff value was chosen
at the point where log(HR) = 0. Cutoff repeatability was checked with
1000 bootstrap replication sample.
2.3.2 | Importance of the covariate
We assessed the importance of NLR as predictor based on their
bootstrap inclusion fractions, when 1000 replications were run in the
Cox PH model. We used a hierarchical selection approach with
log‐likelihood ratio test with cutoff of 0.05, adding in Cox model
the NLR covariate kept fixed the adjusting covariates age >45, male
gender, hemoglobin (Hb) <10.5 g/dL, albumin <4 g/dL, staging IIb‐IV,
and AMC >750/uL.16 In addition NLR was also studied as continuous
variable. All statistical comparisons were 2 sides. The study design
was retrospective. The simple size for this specific research was not
planned. All analyses were performed with Stata SE/10 software.3 | RESULTS
3.1 | Patient characteristics
The median age of the total of 990 patients enrolled in the study was
31 years (17‐69 percentile); 51% females, and 49% males with 45% of
patients symptomatic. The median values of ANC, ALC, and NLR were
6.6 (range 2.0‐18) × 109 cells/L, 1.5 (range 0.36‐4.14) × 109 cells/L, and
4.35 (range 1.10‐18.2), respectively. Details of clinical characteristics
of all patients are shown in (Table 1). Patients received different
combination chemotherapy regimens (Table 2). After a median
follow‐up of 85 months (range 1‐224 mo), 201 patients progressed
or relapsed and 111 patients died from various causes. The estimated
5‐year PFS and OS were 81% (95% CI, 78%‐84%) and 91% (95% CI,
89%‐93%), respectively.
3.2 | Analysis of the cutoff
TheNLRwas determined by dividing the peripheral blood levels of ANC
by ALC at diagnosis. The median NLRwas 4.35 (range 1.10‐18.2). In the
PFS analysis with the flexible restricted cubic spline Cox regression, the
log(HR) for NLR increased linearly and crossed the zero point at around
6.0 (Figure 1). From bootstrap samples (1000 replicates) the mean
cutoff was 5.9 (with a 5‐95 percentile interval range of 4.7‐9.2). On
the basis of this evaluation we chose 6.0 as our threshold value.
Of the 990 patients, 336 (34%) had NLR >6, and of these, 76% had
stage IIB‐IV and 37% had an IPS 3‐7.
TABLE 1 Characteristics of 990 patients with HL enrolled
Variable Median (2.5‐97.5 percentile)
Age 31 (17‐69)
Hb, g/dL 12.3 (7.9‐16.0)
Albumin, g/dL 3.9 (2.5‐5.0)
WBC 109 cells/L 9.20 (3.60‐2.12)
AMC 109 cells/L 0.57 (0.09‐1.58)
ALC 109 cells/L 1.54 (0.36‐4.14)
ANC 109 cells/L 6.59 (2.02‐18.02)
NLR 4.4 (1.1‐18.2)
Factor N, %
Age > 45 209 (21)
Gender, male 487 (49)
Stage IIB‐IV 591 (60)
Hb < 10.5 g/dL 161 (16)
Albumin < 4 g/dL 591 (60)
WBC > 15 000/mm3 116 (12)





Abbreviations: ALC, absolute lymphocyte count; AMC, absolute mono-
cyte count; ANC, absolute neutrophil count; Hb, hemoglobin; HL,
Hodgkin lymphoma; NLR, neutrophil‐lymphocyte ratio; WBC, white
blood cell.
FIGURE 1 Hazard ratio (HR) (in natural logarithm form) associated
with neutrophil‐lymphocyte ratio (NLR). Result as shown from
Cox proportional hazard; restricted cubic spline regression model
(2 degrees of freedom) of NLR expressed as continuous variable.
Vertical line indicates the cutoff value
MARCHESELLI ET AL. 5633.3 | Impact of the therapies
The patients with NLR ≤6 were treated with adriamycin, bleomycin,
vinblastine, and dacarbazine (ABVD) (49%) and bleomycin, etoposide,
adriamycin, cyclophosphamide, vincristine, procarbazine, and predni-









Stanford V 30 (6)
EVE 25 (5)
Radiotherapy 296 (63) 1
Response CHT ± RT N, %
CR 425 (91) 2
PR 19 (4)
SD/PD/EF 25 (5)
Abbreviations: ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; BEA
procarbazine, and prednisone; CAD, lomustine, doxorubicin, and vindesine; CHT,
and vinblastine; EF, early failure; EVE, epirubicin, vinblastine and etoposide; M
progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease; Stan
etoposide, and prednisone; VBM, vinblastine, bleomycin, and methotrexate.
Chi‐square test for response by period of diagnosis, P = .328.were treated with ABVD (45%) and BEACOPP/(MEC)MOPP (40%),
P < .001. Although the therapies in the 2 groups of patients with
NLR ≤6 and NLR >6 were not well balanced, the log‐rank test
between the curves by therapies was not statistically significant for
both PFS (P = .156) and for OS (P = .444) that showed that there
was no impact of the treatments in the survival outcomes.3.4 | Prognostic significance of NLR ratio
3.4.1 | Progression‐free survival
The PFS estimate for NLR ≤6 at 5 years was 84% (95% CI, 81%‐87%)
and 75% (95% CI, 70%‐80%)for NLR >6. Comparison between the
curves showed that this was statistically significant (P < .001,
Figure 2A). In univariate Cox PH regression analysis, NLR >6 showed
a higher risk of disease progression with HR of 1.65 (95% CI,of diagnosis Total
00‐2003 2004‐2007
N, % N, % N, %
44 (56) 180 (68) 484 (49)
39 (15) 25 (9) 230 (23)
36 (14) 26 (10) 150 (15)
32 (13) 35 (13) 67 (7)
2 (1) 0 32 (3)
2 (1) 0 27 (3)
73 (68) 129 (49) 598 (60)
N, % N, % Total
29 (90) 232 (87) 886 (89)
9 (3) 9 (3) 37 (4)
17 (7) 25 (9) 67 (7)
COPP, bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine,
chemotherapy; CR, complete response; EBV, epidoxorubicin, bleomycin,
OPP, mechlorethamine, vincristine, procarbazine, and prednisone; PD,
ford V, doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin,
FIGURE 2 Kaplan‐Meier curves of A, progression‐free survival (PFS) and B, overall survival (OS) stratified by neutrophil lymphocyte ratio (NLR)
cutoff
564 MARCHESELLI ET AL.1.25‐2.18, P = .001) (Table 3). Multivariate analysis, after adjusting for
age >45 years, male gender, Hb <10.5 g/dL, albumin <4/g/dL, stage
IIB‐IV (IPS factors), and AMC >750/uL, showed that the risk remained
high with HR of 1.44 (Table 3). Furthermore, in multivariate Cox PH
regression analysis relating to NLR as a continuous parameter, the
HR increased by 1.03 (95% CI, 1.01‐1.04; P = .001) for any linear
increase of one unit.
We also evaluated the prognostic effect of NLR ≤6 and >6 in
patients with early (I‐IIA) and advanced stage (IIB‐IV); the log‐rank test
between the curves was statistically significant for both groups
(P = .029 for early stage, and P = .033 for advanced stage patients,
respectively, Figure 3a,b).TABLE 3A PFS by NLR in univariate and multivariate Cox PH
regression
PFS 5‐y PFS % Univariate
NLR (95% CI) HR (95% CI) P
≤6 (n = 654, 66%) 84 (81‐87) 1.00
>6 (n = 336, 34%) 75 (70‐80) 1.65 (1.25‐2.18) .001
Multivariate
HR (95% CI) P
NLR 1.44 (1.07‐1.94) .016
Age >45 1.77 (1.31‐2.41) <.001
Male 1.15 (0.81‐1.52) .344
Hb <10.5 g/dL 1.62 (1.15‐2.28) .006
Albumin <4 g/dL 1.17 (0.85‐1.61) .346
Stage IIB‐IV 1.10 (0.77‐1.53) .582
AMC >0.75 109/L 1.55 (1.15‐2.08) .004
BIF NLR >6: 70%
Abbreviations: AMC, absolute monocyte count; BIF, bootstrap inclusion
frequencies, log‐likelihood ratio test over 1000 bootstrap resamples with
cutoff 0.05; 95% CI, confidence interval 95%; Cox PH, Cox proportional
hazard regression; Hb, hemoglobin; HR, hazard ratio; NLR, neutrophil‐lym-
phocyte ratio; PFS, progression‐free survival.3.4.2 | Overall survival
The OS for NLR ≤6 estimated at 5 years was 92% (95% CI, 90%‐94%)
and for NLR >6 was 88% (95% CI, 84%‐92%). Comparison between
the curves was statistically significant (P = .002, Figure 2B). In univari-
ate Cox PH regression analysis NLR >6 showed a higher risk of death
with HR of 1.82 (Table 3b). Multivariate analysis, after adjusting for
age >45 years, male gender, Hb <10.5 g/dL, albumin <4/g/dL, stage
IIB‐IV (IPS factors), and AMC >750/uL, showed that the risk remained
high with HR of 1.54 (95% CI, 1.03‐2.29). Furthermore, in multivariate
Cox PH regression analysis considering NLR as a continuous parame-
ter, HR increased by 1.03 (95% CI, 1.01‐1.06, P = .014) for any linear
increase of one unit.TABLE 3B OS by NLR in univariate and multivariate Cox PH
regression
OS 5‐y OS % Univariate
NLR (95% CI) HR (95% CI) P
≤6 (n = 654, 66%) 92 (90‐94) 1.00
>6 (n = 336, 34%) 88 (84‐92) 1.82 (1.25‐2.65) .002
Multivariable
HR (95% CI) P
NLR 1.54 (1.03‐2.29) .034
Age >45 2.78 (1.88‐4.09) <.001
Male 1.10 (0.75‐1.62) .621
Hb <10.5 g/L 1.40 (0.89‐2.21) .145
Albumin <4 g/dL 1.27 (0.82‐1.99) .289
Stage IIB‐IV 1.38 (0.87‐2.20) .170
AMC >0.75 109/L 1.53 (1.02‐2.28) .038
BIF NLR >6: 56%
Abbreviations: AMC, absolute monocyte count; BIF, bootstrap inclusion
frequencies, log‐likelihood ratio test over 1000 bootstrap resamples with
cutoff 0.05; 95% CI, confidence interval 95%; Cox PH, Cox proportional
hazard regression; Hb, hemoglobin; HR, hazard ratio; NLR, neutrophil‐
lymphocyte ratio; OS, overall survival.
FIGURE 3 A, Progression‐free survival (PFS) in early stage (I‐IIA) group stratified by neutrophil‐lymphocyte ratio (NLR); B, PFS in advanced stage
(IIB‐IV) group; stratified by NLR; C, overall survival (OS) in early stage(I‐IIA) group stratified by NLR; D, OS in advanced stage (IIB‐IV group) stratified
by NLR
MARCHESELLI ET AL. 565We also evaluated the prognostic effect of the NLR ≤6 and >6 in
groups of patients with early (I‐IIA) as well as advanced stage (IIB‐IV);
the log‐rank test between the curves was statistically significant only
for the advanced stage group (P = .036, Figure 3D).
We also evaluated the prognostic role of ANC. As cutoff, deter-
mined with the same methodology used for NLR, we have found
ANC 6.5 × 109/L. By univariate analysis ANC had only a weak prog-
nostic impact power for PFS (HR 1.34, 95% CI, 1.01‐1.77, P = .041) or
OS (HR 1.41, 95% CI, 0.97‐2.06, P = .074). By multivariate analysis,
(after adjusting for age >45, male gender, Hb <10.5 g/dL, albumin
<4/g/dL, stage IIb‐IV (IPS factors), and AMC >750/uL), ANC had no
prognostic impact.4 | DISCUSSION
The NLR is considered a simple and strong parameter for evaluating
both inflammatory (neutrophils) and immune (lymphocyte) responses
relating to prognosis in cancer patients.8 In this regard, a number of
studies have demonstrated the prognostic value of NLR at diagnosis
and prior to therapy in patients with solid tumors.8 In hematological
malignancies, like DLBCL, high NLR3,7,17–19 has also been associated
with a poor prognosis and the results reported in our study on a differ-
ent type of lymphoma—NS‐HL are in line with these findings on
DLBCL.
In HL, low ALC,1 high AMC,2 and low lymphocyte to monocyte
ratios2,7 are associated with a poor prognosis. However until now,
only a few studies have analyzed the prognostic significance of
ANC and NLR in patients with HL. In 2012 Koh et al10 reported
results on 312 patients with classical HL, including 177 with NS‐HL.
After evaluation of all 312 patients, they concluded that NLR is an
independent prognostic factor, which may help to stratify patients
considered as low risk on the basis of the IPS. Here in our study weevaluated a much larger cohort of 990 patients with NS‐HL and after
extensive statistical analysis we chose 6.0 as the NLR cutoff value.
Overall, NS‐HL patients with a NLR <6 had a and statistically signifi-
cant better outcome in terms of both PFS and OS. In multivariate
analysis the NLR remained an independent prognostic factor, along
with other parameters like age >45, male gender, Hb <10.5 g/dL,
albumin <4/g/dL, stage IIB‐IV, and AMC >750/uL. Furthermore,
unlike the IPS, NLR, at least regarding PFS, is a prognostic factor that
is also applicable to patients with early stage disease. The reason for
this correlation of NLR with poor prognosis is largely unknown. How-
ever, in this respect it has been reported that normal neutrophils are
able to suppress T‐cell function, while activated neutrophils have
increased levels of arginase 1, which also cause T‐cell suppression.20
In addition to contributing to T‐cell immune suppression, neutrophils
may also exhibit tumor‐promoting capabilities, like the induction of
angiogenesis and enhancement of tumor spread by enhancing the
expression of matrix metalloproteinase 9.10
Indeed, one of the established “classical” IPS parameters in HL is
peripheral blood leukocytosis, mainly because of an increased neutro-
phil count, and this has been validated extensively.21 In our cohort,
however, we would like to emphasize that there was no correlation
between the absolute neutrophil number and prognosis. We have no
ready explanation for this observation but it could theoretically be
due to the fact that inflammation alone is insufficient to determine
prognosis, and only when linked to decreased host immunity status,
does it gain more powerful prognostic impact, as reflected by the
impressive predictive value of NLR.
Our study has some obvious limitations that relate to the retro-
spective nature of the research design. On the other hand, its strength
includes the large NS‐HL sample size, long follow‐up, and the accuracy
of the cutoff determination based on a large cohort of cases.
In conclusion, here we show that NLR is a strong and independent
prognostic parameter in NS‐HL, inexpensive to perform, and simple to
566 MARCHESELLI ET AL.apply. We, like many others in this field, await with much expectation
the future development of tailored medicine and the routine introduc-
tion of simpler and cheaper methods for the study of gene expression
profiles capable of predicting response to therapy and eventual out-
come. Until then we feel that NLR, possibly in combination with IPS
factors and AMC, could serve as a useful guide for physicians in their
routine management of patients with NS‐HL.
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